Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INO
INO logo

INO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Inovio Pharmaceuticals Inc (INO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.180
1 Day change
1.72%
52 Week Range
2.980
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

INO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term technical strength and extremely bullish options positioning, but the lack of recent news, no strong proprietary buy signal, neutral insider/hedge fund activity, and only neutral Wall Street coverage make this a weak long-term entry. If the investor is unwilling to wait for a better setup, the current data still does not support an outright buy.

Technical Analysis

INO is trading at 1.175 after closing below the previous close of 1.22. The MACD histogram is positive and expanding, which supports short-term momentum. However, RSI_6 at 76.508 is elevated and suggests the stock is stretched rather than attractively priced. Moving averages are converging, indicating the trend is not yet firmly established. Key levels show pivot at 1.155, with resistance at 1.232 and 1.279, and support at 1.079 and 1.032. Overall, the chart shows a short-term bounce attempt, but not a clean long-term bullish trend.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is extremely bullish on paper, with a very low open interest put-call ratio of 0.03 and zero put volume versus strong call activity. Call open interest is 60,580 versus put open interest of only 1,936, and today's option volume was heavily call-skewed. Implied volatility is extremely high at 709.13, with IV percentile 90.48 and IV rank 70.71, showing the market expects very large swings. This supports speculative bullish sentiment, but it also indicates a very expensive and unstable options environment rather than a clean long-term buy signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
4

Positive Catalysts

  • ["Very bullish options positioning with heavy call dominance", "Positive and expanding MACD histogram", "Price is near the pivot area, which may support a short-term rebound", "Analyst target remains above current price at $2.50"]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst", "RSI is elevated, suggesting the stock is short-term extended", "No strong proprietary buy signal from AI Stock Picker or SwingMax", "Hedge funds and insiders are both neutral", "H.C. Wainwright cut the target from $3 to $2.50 and kept only a Neutral rating", "No recent congress trading data", "Financial snapshot unavailable, so there is no evidence here of strong fundamental improvement"]

Financial Performance

Latest quarter financial data was not available due to an error in the snapshot, so there is no reliable quarterly revenue or earnings growth readout to support a long-term buy case. Because the latest quarter season cannot be confirmed from the provided data, fundamentals cannot be used as a positive driver here.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend is mixed to cautious: H.C. Wainwright lowered its price target to $2.50 from $3 after the Q1 report and maintained a Neutral rating. That implies Wall Street still sees upside from the current price, but the tone is not strongly bullish. The pros view is limited upside potential versus the current price, while the cons view is that dilution/share count growth is pressuring value and support is not strong enough for a confident long-term buy.

Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
Wall Street analysts forecast INO stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.160
sliders
Low
3
Averages
7.33
High
13
Current: 1.160
sliders
Low
3
Averages
7.33
High
13
H.C. Wainwright
Neutral
downgrade
$3
AI Analysis
2026-06-01
Reason
H.C. Wainwright
Price Target
$3
AI Analysis
2026-06-01
downgrade
Neutral
Reason
H.C. Wainwright lowered the firm's price target on Inovio to $2.50 from $3 and keeps a Neutral rating on the shares post the Q1 report. The firm cites increasing share counts for the target cut.
Piper Sandler
Edward Tenthoff
Overweight
maintain
$5 -> $6
2025-11-14
Reason
Piper Sandler
Edward Tenthoff
Price Target
$5 -> $6
2025-11-14
maintain
Overweight
Reason
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Inovio to $6 from $5 and keeps an Overweight rating on the shares. The firm notes the company ended Q3 with cash of $50.8M and subsequently raised gross proceeds of $28.75M bringing pro forma cash to $77.3M, expected to fund operations into Q3 2026 through INO-3107 approval.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INO
Unlock Now

People Also Watch